Tests pirtobrutinib with chemotherapy in relapsed diffuse large B-cell lymphoma

Trial details

Who runs it

Ruijin Hospital

Trial code

NCT07122609

Record updated

14 August 2025

Original description

This is a prospective, single arm trial in patients with ≥ 18 years with relapsed and refractory DLBCL. Aim of this study is to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab, gemcitabine, and oxaliplatin with or without polatuzumab vedotin (Pirto-R-GemOx±pola) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) previously treated with covalent BTK inhibitors.Read full original descriptionShow less

A Study of Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin (Pirto-R-GemOx±Pola) in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This is a prospective, single arm trial in patients with ≥ 18 years with relapsed and refractory DLBCL. Aim of this study is to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab, gemcitabine, and oxaliplatin with or without polatuzumab vedotin (Pirto-R-GemOx±pola) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) previously treated with covalent BTK inhibitors.

Inclusion: Histologically confirmed DLBCL (2016 WHO criteria) of MCD, BN2, N1 subtypes, double-expressor, intravascular large B-cell lymphoma, or other BTK-sensitive subtypes; Disease progression/relapse after covalent BTK inhibitor therapy; ≥1 measurable lesion (nodal >15mm/extranodal >10mm) on PET/CT within 28 days; Eastern Cooperative Oncology Group (ECOG) 0-2; age ≥18 years; Adequate organ function:; ANC ≥0.5×10⁹/L ；Platelets ≥50×10⁹/L (transfusion-independent)；Bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN；Cr ≤1.5×ULN or CrCl ≥30mL/min；LVEF ≥50% (NYHA class <III); Life expectancy >3 months; Sign the written ICF, and be able to comply with the visits and related procedures stipulated in the protocol; Female subjects of childbearing potential or male subjects with female partners of childbearing potential must use effective contraception throughout the treatment period and for 90 days after the last treatment.

Exclusion: Major surgery within 4 weeks prior to treatment (excluding vascular access placement or biopsy); Contraindications or hypersensitivity to any drug in the combination regimen; Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's judgment, may compromise patient safety or compliance with study procedures; Poorly controlled cardiac clinical symptoms or diseases, including:; NYHA Class II or higher heart failure ii. Unstable angina iii. Myocardial infarction within 1 year iv. Clinically significant supraventricular or ventricular arrhythmias requiring treatment/intervention; Active hemorrhage; Poorly controlled systemic bacterial, viral, fungal, or parasitic infections (excluding fungal nail infections), or other clinically significant active diseases that render patients unsuitable for trial participation per investigator assessment; Patients with:Active chronic hepatitis B or C.Positive HBsAg and/or HBcAb or HCV antibodies at screening must demonstrate HBV DNA ≤2,500 copies/mL (or 500 IU/mL) to exclude active HBV/HCV infection requiring treatment.HBsAg/HBcAb-positive patients must receive antiviral prophylaxis; HIV-infected patients and/or AIDS patients; Inability to swallow tablets, malabsorption syndrome, or any gastrointestinal disorder/ dysfunction that may impair drug absorption; Psychiatric disorders or inability to provide informed consent; Any other condition deemed unsuitable for study participation by the investigator; DLBCL with central nervous system (CNS) or meningeal involvement; Histologically transformed DLBCL; Lactating or pregnant women.

ClinicalTrials.gov NCT07122609